EUCAST technical note on Amphotericin B.
The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has determined breakpoints for amphotericin B for Candida spp. This Technical Note is based on the EUCAST amphotericin B rationale document (available on the EUCAST website: http://www.eucast.org). Species-specific breakpoints for C. albicans, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis are S: MIC ≤1 mg/L, R: MIC > 1 mg/L. There are insufficient data to set breakpoints for other species. The breakpoints are based upon pharmacokinetic data, epidemiological cut-ff values and clinical experience. Breakpoints will be reviewed regularly.
Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria. cornelia.lass-floerl@i-med.ac.at
C
C
Lass-Flörl
M C
MC
Arendrup
J-L
JL
Rodriguez-Tudela
M
M
Cuenca-Estrella
P
P
Donnelly
W
W
Hope
D000666:Amphotericin B / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology*; D025141:Drug Resistance, Fungal; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000592:standards
D000935:Antifungal Agents; D000666:Amphotericin B